Company Monitoring Page for Daiichi-Sankyo

latest headlines for company on cafepharma

AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval
Fierce Biotech
Fri, 12/6/24 - 09:51 am
Tags:
AstraZeneca, Daiichi Sankyo, Dato-DXd
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Fierce Pharma
Tue, 11/19/24 - 07:14 pm
Tags:
AstraZeneca, Daiichi Sankyo, Enhertu, UK, NICE
AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again
Fierce Biotech
Tue, 11/12/24 - 08:44 pm
Tags:
AstraZeneca, Daiichi Sankyo, lung cancer, FDA, Dato-DXd, Enhertu
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Pharmaphorum
Fri, 11/8/24 - 11:37 am
Tags:
Daiichi Sankyo, Alteogen, Enhertu, cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
Tags:
FDA, Bridge Bio, acoramidis, AstraZeneca, Daiichi Sankyo, Dato-DXd, Vertex Pharmaceuticals, Vanza Triple, PTC Therapeutics, Upstaza, Bristol Myers Squibb, Opdivo
AstraZeneca's experimental drug disappoints in breast cancer survival trial
Reuters
Mon, 09/23/24 - 11:29 am
Tags:
AstraZeneca, Daiichi Sankyo, clinical trials, breast cancer, Dato-DXd
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Medical Marketing and Media
Sun, 09/22/24 - 09:46 pm
Tags:
Daiichi Sankyo, AstraZeneca, breast cancer, metastatic breast cancer, Enhertu, DTC ads
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Fierce Pharma
Thu, 09/19/24 - 11:06 am
Tags:
artificial intelligence, Bayer, Daiichi Sankyo, Argenx
ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases
Clinical Trials Arena
Tue, 09/17/24 - 11:20 am
Tags:
ESMO, breast cancer, Daiichi Sankyo, Enhertu, metastatic breast cancer, clinical trials
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Reuters
Tue, 09/17/24 - 09:51 am
Tags:
Daiichi Sankyo, Merck, patritumab deruxtecan, clinical trials, non-small cell lung cancer
AstraZeneca steps out from Daiichi's shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Fierce Biotech
Sun, 09/15/24 - 06:25 pm
Tags:
AstraZeneca, Daiichi Sankyo, antibody-drug conjugate
Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data
Fierce Biotech
Mon, 09/9/24 - 11:30 am
Tags:
Merck, Daiichi Sankyo, I-DXd, small cell lung cancer, clinical trials
EU starts review of Enhertu in HER2-ultra-low breast cancer
Pharmaphorum
Mon, 08/19/24 - 09:56 am
Tags:
EMA, Europe, AstraZeneca, Daiichi Sankyo, breast cancer, Enhertu
Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo
Fierce Biotech
Tue, 08/6/24 - 11:20 am
Tags:
Merck, Harpoon Therapeutics, Daiichi Sankyo, small cell lung cancer
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
Clinical Trials Arena
Fri, 08/2/24 - 11:50 am
Tags:
Daiichi Sankyo, Merck, clinical trials, I-DXd, small cell lung cancer
After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds
Fierce Pharma
Mon, 07/29/24 - 10:51 am
Tags:
AstraZeneca, Daiichi Sankyo, Enhertu, NICE, UK, HER2-low breast cancer
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
BioSpace
Mon, 07/1/24 - 11:14 am
Tags:
Daiichi Sankyo, Seagen, patents, Enhertu
FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
Reuters
Thu, 06/27/24 - 11:18 am
Tags:
Merck, Daiichi Sankyo, cancer, FDA, patritumab deruxtecan, antibody-drug conjugate
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
Tags:
FDA, Eli Lilly, donanemab, Alzheimer's disease, Adaptimmune, afami-cel, advanced synovial sarcoma, Lykos Therapeutics, MDMA, PTSD, Bristol Myers Squibb, KarXT, schizophrenia, Daiichi Sankyo, AstraZeneca, Dato-DXd, non-small cell lung cancer
ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer
Fierce Pharma
Sun, 06/2/24 - 02:46 pm
Tags:
ASCO 2024, AstraZeneca, Daiichi Sankyo, Enhertu, breast cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.